4 research outputs found
Recommended from our members
Dasabuvir: a new direct antiviral agent for the treatment of hepatitis C
Introduction: Treatment of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) has revolutionized the care of infected patients. Among these novel compounds are non-nucleoside analogs, which bind viral RNA-dependent RNA polymerase resulting in a conformational change inhibiting RNA synthesis.
Areas covered: Efficacy and tolerability of treatment regimens containing the non-nucleoside analog polymerase inhibitor
dasabuvir
(ABT-333).
Expert opinion: Dasabuvir-containing regimens achieve high rates of sustained virologic response in HCV genotype 1a and 1b-infected patients when combined with other DAAs, namely paritaprevir (ABT-450), ritonavir and ombitasvir (ABT-267). In the populations studied, dasabuvir seems to be well tolerated and safe. The major limitations of this novel drug are its genotype-restricted activity, the necessity to include ribavirin for HCV genotype 1a and the emergence of resistance if not combined with other DDAs
Recommended from our members
Transarterial Catheter Embolization to Control Massive Intra-Abdominal Bleeding in a Case of Large Ruptured Hepatocellular Carcinoma 501
Recommended from our members
A Rare Case of Myeloma Associated Systemic AL Amyloidosis Presenting with Infiltrative Liver Disease and Liver Failure 512
Dasabuvir: a new direct antiviral agent for the treatment of hepatitis C
Introduction: Treatment of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) has revolutionized the care of infected patients. Among these novel compounds are non-nucleoside analogs, which bind viral RNA-dependent RNA polymerase resulting in a conformational change inhibiting RNA synthesis.
Areas covered: Efficacy and tolerability of treatment regimens containing the non-nucleoside analog polymerase inhibitor
dasabuvir
(ABT-333).
Expert opinion: Dasabuvir-containing regimens achieve high rates of sustained virologic response in HCV genotype 1a and 1b-infected patients when combined with other DAAs, namely paritaprevir (ABT-450), ritonavir and ombitasvir (ABT-267). In the populations studied, dasabuvir seems to be well tolerated and safe. The major limitations of this novel drug are its genotype-restricted activity, the necessity to include ribavirin for HCV genotype 1a and the emergence of resistance if not combined with other DDAs